Thought Leader Select’s Meade to Address ExL Pharma KOL Conference

June 17, 2014 · Leave a comment

Thought Leader Select continues with a busy summer schedule of conference sponsorships, with the company’s support of ExL Pharma’s Fifth KOL Relationship Summit in Philadelphia.  Paul Meade, founder and President of Thought Leader Select, will address attendees at one of the must-attend events for American life sciences companies, coming on the heels of the company’s successful sponsorship of the Canadian Healthcare Licensing Association’s Summer Meeting and the Medical Science Liaison Society’s Global Conference in Boston.

The conference, geared to medical affairs and marketing professionals tasked with outreach to and collaboration with key opinion leaders (KOLs) in the medical community, will take place June 24-25 at the Hyatt Bellevue in the Center City area of downtown Philadelphia.  The Summit will feature a variety of speakers from companies within the life sciences industry, as well as consultants from the world of KOL strategy, CRM software, medical communications, and digital engagement platforms for healthcare.

Thought Leader Select’s Meade will lead an afternoon session on day one of the event, speaking on the topic, “Can Industry Still Work Effectively with KOLs?” During his talk, Meade will illustrate many of the challenges facing both industry representatives and thought leaders in the medical community, including transparency, scrutiny, and ... read more »

TAGS:                               

MSL Society Announces Inaugural Global Conference and Gala

February 7, 2013 · Leave a comment

For Immediate Release

February 7, 2013 (Chapel Hill, NC) The Medical Science Liaison Society (MSL Society) is planning its first global conference and gala for April 2013.

The event will take place at Philadelphia’s Hyatt at the Broadview on South Broad Street, from April 1-3.  The 2013 MSL Society Conference and Gala is the first event of its kind, a tangible extension of the non-profit organization’s mission to bring together global medical affairs professionals for education and networking in an effort to support the profession.

Attendees will include Medical Affairs and MSL Leadership, as well as other professionals focusing on key topic including KOL access, HEOR, clinical trials, clinical investigation, key opinion leader relationship management, and medical communications.  The emerging roster of speakers includes luminaries from the world of medical affairs, including Dr. Stewart Rosen, Vice President of Medical Affairs at Quintiles, Dr. Robert Ang, Vice President of Medical Affairs at Cadence Pharmaceuticals, and Dr. Elizabeth Kupferer, Director of Medical Affairs at Sequenom.  

Highlights of the three-day event include a welcome reception on day one, followed by a full day of education and networking, the gala dinner to culminate day two, and a final round of education and networking on day three.

“We’ve planned our first live conference with the needs ... read more »

TAGS:                                                         

International Pharma Chooses Thought Leader Select for Women’s Health Initiative with Key Opinion Leaders, Centers of Excellence

November 6, 2012 · Leave a comment

November 6, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in Canada focused on key opinion leaders and medical centers of excellence in women’s health with an international biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products aimed at improving the health of women, approached Thought Leader Select for support in a variety of collaborative efforts with leading physicians and other health care professionals at leading universities, medical schools, teaching hospitals, and specialty clinics.  The key opinion leaders represent medical experts within the Canadian obstetrics and gynecology community, with areas of sub-specialty including fertility and the treatment of uterine tumors.

Known for the versatility of applications for its in-house research and analysis, Thought Leader Select’s research group will analyze the skills and experience of specialists in multiple areas where they collaborate with leading physicians and other health care professionals, including registered nurses, physician assistants, nurse practitioners, clinical pharmacists, and medical researchers, to advance the science of medicine and patient care in women’s health, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.

Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening collaborative ... read more »

TAGS:                                                               

Top 30 Global Biopharmaceutical Company Chooses Thought Leader Select for Blood Disorder KOL Partnership

June 14, 2012 · Leave a comment

June 14, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a global engagement in blood disorders with a top 30 global biopharmaceutical company.

The biopharmaceutical company, part of a select group of global leaders in drug development for a product in development to treat iron overload in the body, approached Thought Leader Select for support with its launch activities across multiple global markets.  To meet the strategic needs of the company’s pre-launch for a new blood disorders treatment, Thought Leader Select will deploy its in-house research group for an assessment of key opinion leaders in the area of chelation therapy.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following geographic areas:

  • United States
  • Europe
  • Japan
  • Pacific Rim
  • Middle East

For the global assessment, the Thought Leader Select research group will identify 100 physicians appropriate for compliant engagement in support of drug development for blood disorders.

In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought ... read more »

TAGS:                                                     

Top 10 Global Biopharmaceutical Company Tabs Thought Leader Select for Infectious Disease Partnership

April 26, 2012 · Leave a comment

April 26, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of an inter-disciplinary infectious disease engagement with a top 10 global biopharmaceutical company.

The biopharmaceutical company, part of a select group of global leaders in drug development for the treatment of infectious diseases, approached Thought Leader Select for support with its development pipeline across the Canadian market.  To meet the combined strategic needs of the company’s emerging pipeline in treating conditions like HIV and Hepatitis-C, Thought Leader Select will deploy its in-house research group for a multi-disciplinary assessment of the key opinion leader community in infectious diseases.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following areas:

Gastroenterology

Hepatology

Infectious Disease

Internal Medicine

For the first wave of the assessment, the Thought Leader Select research group will identify 50 physicians appropriate for compliant engagement in support of drug development for infectious diseases, across multiple Canadian provinces.

In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought leaders, ... read more »

TAGS:                                                                           

Top 20 Global Pharma Chooses Thought Leader Select for Urology Partnership

April 18, 2012 · Leave a comment

April 18, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a urology engagement with a top 20 global pharmaceutical company.

The pharmaceutical company, a global leader in drug development for urological conditions, approached Thought Leader Select for support with its existing portfolio of medicines, as well as new drugs in its development pipeline across the Canadian market.  To meet the combined strategic needs of the company’s existing portfolio as well as its emerging pipeline, Thought Leader Select will deploy its in-house research group for a two-part assessment of the key opinion leader community in urology.

For the first wave of the assessment, the Thought Leader Select research group will validate the skills and experience of the urology specialists that currently comprise the company’s KOL roster.  In addition, Thought Leader Select will identify new physicians appropriate for the panel, bringing the total roster to 40 thought leaders across multiple Canadian provinces.

In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as ... read more »

TAGS:                                       

Understanding the Sunshine Act—Part Two

April 10, 2012 · Leave a comment

Industry Insights from Kristen Smithwick

Last week proved to be another interesting week for the developing Sunshine Act. Senators Chuck Grassley (R-IA) and Herb Kohl (D-WI) sent a pivotal memo to Acting CMS Administrator Marilyn Tavenner. The senators urged the agency to publish a final rule no later than June 2012 and to respond to several questions related to implementation.

Senators Grassley and Kohl want the agency to begin gathering transparency data this year, and they’re not willing to give CMS any wiggle room for delays. To meet the senators’ timeline, CMS will need to address comments and recommendations from numerous interested parties, especially the Pharmaceutical Research and Manufacturers of America (PhRMA), the Advanced Medical Technology Association (AdvaMed), and the Biotechnology Industry Organization (BIO). We covered a number of areas questioned in Part 1 of this blog. In this post, we’ll mention just a few additional areas of concern.

Definition of Applicable Manufacturer and Separate vs. Consolidated Reporting – Questions and concerns abound when it comes to defining applicable manufacturers, especially as the definition impacts requirements for separate vs. consolidated reporting for entities with common ownership. The challenge for CMS will be to ensure the definitions of applicable manufacturers and common ownership are broad enough to meet the public’s demand for transparency, while being specific enough to protect the ... read more »

TAGS:                                                             

Understanding the Sunshine Act—Part One

March 27, 2012 · Leave a comment

Industry Insights from Kristen Smithwick

Albeit a bit late, the U. S.  Centers for Medicare and Medicaid Services (CMS) issued a proposed rule on the Patient Protection & Affordable Care Act’s Physician Payments Sunshine Provision (also known as the “Sunshine Act”) to implement it as law.

CMS invited comments on the proposed rule through mid-February 2012, and a recent webcast, sponsored by PharmaLive’s Pharmalot, featured key facts and summaries of comments on the proposed rule. Working for a provider of research and consulting to the biopharmaceutical, medical device, and diagnostics industries on relationships with physicians and other health care providers, I enjoyed the opportunity to join the webcast, led by experts from Buchanan Ingersoll & Rooney, P.C., and am eager to share some of my key takeaways.

As mentioned in previous Thought Leader Select Blog posts, the Sunshine Act, as with many laws and regulations, is full of unintended consequences – some positive and some negative. Lance K. Stell, medical ethics teacher at Davidson College and Carolinas Medical Center, reports in his USA Today op-ed piece that the “Sunshine Act will cost far more than the $224 million estimated for just the first year of compliance” and that “the biggest cost will be the valuable, socially useful physician-industry collaborations that simply won’t occur.” Of course, the idea of ... read more »

TAGS:                                                       

Use of Social Media in Healthcare

February 9, 2011 · Leave a comment

Trendspotting with Kristen Smithwick

There’s been plenty of talk in recent months about the impact of social media on the future of healthcare. Many stakeholders are carving out their own space within the social media sphere, with customized strategies that fit their respective ambitions and external pressures, such as regulatory guidelines.

Biopharmaceutical companies are beginning to craft social media strategies and experiment with different activities; the FDA is reviewing potential social media guidelines; and medical professionals are individually using social media in a variety of ways. A recent article in MedAd News says that “according to Manhattan Research, 89 million American adults used social media for health in 2010”. That’s a staggering figure –nearly 30% of the American population used social media sites to discuss health-related issues. Evidence that the use of social media in healthcare is here to stay has even hit pop culture, when last week’s episode of Grey’s Anatomy featured Dr. Bailey tweeting her surgery play-by-play. Upon seeing how much visibility his department could attain within the medical community, even Chief Webber jumped on board!

At Thought Leader Select, we’re also examining how to better understand the ways that thought leaders in the medical community use social media. In our quest to stay on top of the trends among medical experts, we’d ... read more »

TAGS:                                 

Thought Leader Select announces 50 Percent Annual Growth for 2010

February 3, 2011 · Leave a comment

New press release out today from the offices of Thought Leader Select:

Thought Leader Select announces 50 Percent Annual Growth for 2010

FOR IMMEDIATE RELEASE

February 3, 2010 (CHAPEL HILL, NC)-Thought Leader Select, a Research Triangle, NC-based research and consulting company serving the biopharmaceutical and healthcare industries, announces 50 percent year-over-year growth for 2010.

Founded in 2006, Thought Leader Select is a specialty firm dedicated to strengthening industry collaborations with medical experts for the development of next generation medicines. The company’s practice area focuses on three aspects of working with key opinion leaders (KOLs) in the medical community:  identification and profiling, mapping, and engagement.

During the 2010 fiscal year, the company grew its revenues by 50 percent over fiscal year 2009, according to Kristen Smithwick, Vice President of Business Development, Marketing, and Strategic Planning.  “We had a very strong year in 2010, and we have solidified our position as one of the preeminent thought leader engagement companies in the marketplace,” stated Smithwick.

The company marked 2010 by generating a record 28 customized research assessments for 10 of the top 50 global biopharmaceutical companies (measured by revenue).  Thought Leader Select identified and profiled over 2500 KOLs in 30 countries. The medical experts represented multiple therapeutic areas and disease states, including neurology, ophthalmology, cardiology, endocrinology, and immunology.

Thought Leader Select used its industry-leading “deep profiling” methodology to ... read more »

TAGS:                                                     

Older posts »